Eli Lilly: FDA grants fast review of baricitinib for lupus
(CercleFinance.com) - Eli Lilly on Thursday said that US regulators have granted a priority review for the company's application to market baricitinib for the treatment of systemic lupus erythematosus.
The designation means that the US Food and Drug Administration is expected to expedite the review of the new medicine, considering that its treats "serious conditions."
Baricitinib is already approved in over 50 countries for the treatment of adults with rheumatoid arthritis.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The designation means that the US Food and Drug Administration is expected to expedite the review of the new medicine, considering that its treats "serious conditions."
Baricitinib is already approved in over 50 countries for the treatment of adults with rheumatoid arthritis.
Copyright (c) 2018 CercleFinance.com. All rights reserved.